trending Market Intelligence /marketintelligence/en/news-insights/trending/fkn46z0nqcwbv8xml88xma2 content esgSubNav
In This List

Acon Investments, Humus Capital acquire biosimilar company Biosidus

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acon Investments, Humus Capital acquire biosimilar company Biosidus

Private equity firms Acon Investments LLC and Humus Capital Partners LLC acquired a majority stake in Biosidus SA and Biosidus Farma SA.

Buenos Aires, Argentina-based Biosidus develops biosimilars — or identical copies of medicines sold by a different company — with a focus on treating chronic kidney failure, cancer and multiple sclerosis, among others.

Washington, D.C.-based Acon and Buenos Aires-based Humus plan to continue Biosidus' international expansion plan.

Financial terms of the deal were not disclosed.